Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Persistent HPV Infection Raises Risk of Anogenital Cancers

By LabMedica International staff writers
Posted on 21 Jul 2016
Women with a history of severe cervical intraepithelial neoplasia, a precancerous condition of the cervix that arises from infection with the human papillomavirus, have a long-term increased risk of developing anal, vulvar, and vaginal cancer.

High-risk human papillomavirus (HPV) is essential for developing high-grade cervical intraepithelial neoplasia (CIN2 and CIN3) and has also been associated with noncervical anogenital cancers. More...
However, limited knowledge exists about the long-term risk for anal, vulvar, and vaginal cancer following CIN2 or CIN3 diagnosis.

Scientists at the Danish Cancer Society Research Center (Copenhagen, Denmark) identified women through Denmark's system of personal identification numbers, which they linked to the Danish Cancer Registry and the Pathology Data Bank to obtain information on verified cases of CIN2 and CIN3, as well as cancer diagnoses. In order to ascertain whether CIN3 was also associated with anal, vulvar, and vaginal cancer, they studied 2.8 million women who were recorded as living in Denmark between 1978 and 2012, following some women for up to 34 years.

Of these women, about 104,000 had CIN3 and about 52,000 had CIN2; the rest of them had no history of these conditions. The study found that when compared with women with no history of the disease, women with CIN3 were 4.2 times more likely to develop anal cancer, four times more likely to develop vulvar cancer, and 17 times more likely to develop vaginal cancer. Women with CIN2 were 2.9 times more likely to develop anal cancer, 2.5 times more likely to develop vulvar cancer, and 8.1 times more likely to develop vaginal cancer than women with no history of the disease.

Susanne K Kjaer, MD, the senior author of study, said, “That while the connection between HPV and cervical cancer is well known, the results of this study add anogenital cancers to the list of potential long-range consequences of HPV infection and could add to support for vaccination against the virus. The HPV vaccine is prophylactic, and if we can prevent HPV infection from occurring in the first place, we can prevent some of these conditions that result from persistent infection. The risk of anal, vulvar, or vaginal cancer was highest in the first year after diagnosis with CIN3. However, the increased risk persisted even when excluding cases that were diagnosed in the first year.” The study was published on June 29, 2016, in the journal Cancer Epidemiology, Biomarkers and Prevention.

Related Links:
Danish Cancer Society Research Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Manual Pipetting Aid
Pipette Controllers macro
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.